Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand
-
Narrated by:
-
By:
About this listen
Access is opening up for Kiwis to a weight loss drug described as a game changer.
Wegovy, made by pharma-co Novo Nordisk, will arrive in pharmacies next week.
It's not funded by Pharmac, so users will have to pay and get a prescription for the weekly injectable.
Calocurb CEO Sarah Kennedy told Ryan Bridge that people need to be aware of both the cost of the drug and the side effect.
She says that over 70% of people using Wegovy will have gastrointestinal problems that range from nausea to diarrhoea, and over 70% of people regain the weight within a year.
Kennedy says lifestyle changes need to be made as well as taking the drug.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.
What listeners say about Sarah Kennedy: Calocurb CEO on Wegovy becoming available in New Zealand
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.